Literature DB >> 25256967

Pharmacology: New therapies and challenges.

A Robinson, C Scully.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25256967     DOI： 10.1038/sj.bdj.2014.811

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


× No keyword cloud information.
  7 in total

Review 1.  Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.

Authors:  Debashish Bose; Funda Meric-Bernstam; Wayne Hofstetter; David A Reardon; Keith T Flaherty; Lee M Ellis
Journal:  Lancet Oncol       Date:  2010-02-18       Impact factor: 41.316

2.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

Review 3.  Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.

Authors:  James D Mellor; Michelle Cassumbhoy; Michael Jefford
Journal:  Asia Pac J Clin Oncol       Date:  2011-06       Impact factor: 2.601

Review 4.  Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Authors:  Matthias Troeltzsch; Timothy Woodlock; Stefanie Kriegelstein; Timm Steiner; Karl Messlinger; Markus Troeltzsch
Journal:  J Can Dent Assoc       Date:  2012       Impact factor: 1.316

Review 5.  Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon.

Authors:  Ketan Sharma; Jeffrey R Marcus
Journal:  Ann Plast Surg       Date:  2013-10       Impact factor: 1.539

6.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976

7.  Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.

Authors:  B Beuselinck; P Wolter; A Karadimou; R Elaidi; H Dumez; A Rogiers; T Van Cann; L Willems; J-J Body; J Berkers; H Van Poppel; E Lerut; P Debruyne; R Paridaens; P Schöffski
Journal:  Br J Cancer       Date:  2012-11-06       Impact factor: 7.640
  7 in total
  1 in total

1.  The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Authors:  Meltem Ozden Yüce; Emine Adalı; Gözde Işık
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.